CYCC stock forecast
Our latest prediction for Cyclacel Pharmaceuticals, Inc.'s stock price was made on the July 19, 2017 when the stock price was at 1.75$.
In the short term (2weeks), CYCC's stock price should outperform the market by 6.73%. During that period the price should oscillate between -11.17% and +26.68%.
In the medium term (3months), CYCC's stock price should outperform the market by 7.51%. During that period the price should oscillate between -23.45% and +60.76%.Get email alerts
Create a solid portfolio with CYCC
About Cyclacel Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company builds a biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -0.34$ per share.
The book value per share is 1.55$
Three months stock forecastJuly 19, 2017
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|